TScan Therapeutics, Inc. TCRX

TCRX Company Overview

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies and related immune therapies for cancer and other serious diseases. The company operates within the biotechnology and immuno-oncology industries, with a primary emphasis on identifying clinically relevant TCR targets and engineering personalized and allogeneic T cell therapies. TScan’s platform is designed to map interactions between T cells and antigens at scale, enabling the discovery of novel therapeutic targets across solid tumors and hematologic malignancies. Its principal revenue sources have historically consisted of collaboration agreements, licensing arrangements, and research funding, as the company remains in the clinical development stage and has not reported commercial product revenue in public filings.

The company was founded in 2018 based on technology developed at Massachusetts General Hospital and Harvard Medical School by researchers including Dr. Stephen Elledge and Dr. Tomasz Kula. TScan evolved from an early-stage platform technology company into a clinical-stage cell therapy developer with multiple investigational TCR-T programs targeting both solid tumors and blood cancers. A distinguishing aspect of the company is its proprietary antigen discovery platform, which is designed to systematically identify targetable peptide-HLA interactions and reduce off-target toxicity risks commonly associated with engineered T cell therapies.